目次

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. RESEARCH OBJECTIVE

3. RESEARCH METHODOLOGY
3.1. OVERVIEW
3.2. DATA FLOW
3.2.1. DATA MINING PROCESS
3.3. PURCHASED DATABASE:
3.3.1. SECONDARY RESEARCH DATA FLOW:
3.4. PRIMARY RESEARCH:
3.4.1. PRIMARY RESEARCH DATA FLOW:
3.4.2. PRIMARY RESEARCH: NUMBER OF INTERVIEWS
3.4.3. PRIMARY RESEARCH: REGIONAL COVERAGE
3.5. APPROACHES FOR
3.5.1. CONSUMPTION & NET TRADE APPROACH
3.6. DATA FORECASTING
3.6.1. DATA FORECASTING
3.7. DATA MODELING
3.7.1. MICROECONOMIC FACTOR ANALYSIS:
3.8. TEAMS AND ANALYST CONTRIBUTION

4. MARKET DYNAMICS
4.1. INTRODUCTION
4.1.1. INNOVATION IN DRUG FORMULATIONS AND DELIVERY SYSTEMS
4.1.2. HEALTHCARE ACCESSIBILITY AND REGULATION
4.1.3. RISING DEMAND FOR NASAL
4.2. DRIVERS
4.2.1. INCREASING INCIDENCE OF RESPIRATORY
4.2.2. GROWING POPULARITY OF SELF-MEDICATION
4.3. RESTRAINTS
4.3.1. STRINGENT REGULATORY GUIDELINES
4.3.2. SIDE EFFECTS AND SAFETY CONCERNS
4.4. OPPORTUNITY
4.4.1. INCREASED DEMAND FOR
4.4.2. DEVELOPMENT OF COMBINATION THERAPIES
4.5. IMPACT ANALYSIS OF COVID-19
4.5.1. IMPACT
4.5.2. IMPACT ON GLOBAL DECONGESTANT MARKET
4.5.3. IMPACT ON MARKET
4.5.4. IMPACT ON PRICING OF GLOBAL DECONGESTANT

5. MARKET FACTOR ANALYSIS
5.1. SUPPLY/VALUE CHAIN ANALYSIS
5.1.1. MANUFACTURING
5.1.2. PACKAGING & LABELLING
5.1.3. DISTRIBUTION AND RETAIL
5.1.4. RETAIL & CONSUMER DEMAND
5.1.5. THREAT OF NEW ENTRANTS
5.1.6. THREAT
5.1.7. BARGAINING POWER OF SUPPLIERS
5.1.8. BARGAINING POWER
5.1.9. INTENSITY OF RIVALRY

6. GLOBAL DECONGESTANT MARKET, BY
6.1. INTRODUCTION
6.1.1. SYNTHETIC DECONGESTANTS
6.1.2. HERBAL DECONGESTANTS
6.1.3. COMBINATION

7. GLOBAL DECONGESTANT MARKET, BY FORMULATION
7.1. INTRODUCTION
7.1.1. NASAL SPRAY
7.1.2. ORAL
7.1.3. TOPICAL

8. GLOBAL DECONGESTANT
8.1. INTRODUCTION
8.1.1. PRESCRIPTION-BASED

9. GLOBAL DECONGESTANT MARKET, BY APPLICATION
9.1. INTRODUCTION
9.1.1. NASAL ALLERGIES
9.1.2. COLD
9.1.3. ASTHMA
9.1.4. RHINITIS
9.1.5. SINUSITIS
9.1.6. NASAL POLYPS
9.1.7. OTHERS

10. GLOBAL DECONGESTANT
10.1. INTRODUCTION
10.1.1. PEDIATRICS
10.1.2. GERIATRICS

11. GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL
11.1. INTRODUCTION
11.1.1. HOSPITAL PHARMACIES
11.1.2. DRUG STORES & RETAIL PHARMACIES
11.1.3. ONLINE PHARMACIES

12. GLOBAL DECONGESTANT MARKET, BY REGION
12.1. NORTH AMERICA
12.1.1. US
12.1.2. EUROPE
12.1.3. SOUTH AMERICA
12.1.4. MIDDLE EAST & AFRICA

13. COMPETITIVE
13.1. INTRODUCTION
13.2. MARKET SHARE ANALYSIS, 2024

14. COMPANY
14.1. PFIZER.
14.1.1. COMPANY OVERVIEW
14.1.2. PRODUCTS OFFERED
14.1.3. SWOT ANALYSIS
14.1.4. KEY STRATEGY
14.2. CIPLA LTD.
14.2.1. PRODUCTS OFFERED
14.2.2. SWOT ANALYSIS
14.3. GLAXOSMITHKLINE (GSK)/ PANADOL
14.3.1. COMPANY OVERVIEW
14.3.2. PRODUCTS OFFERED
14.3.3. SWOT ANALYSIS
14.3.4. KEY STRATEGY
14.4. JOHNSON & JOHNSON
14.4.1. COMPANY OVERVIEW
14.4.2. PRODUCTS OFFERED
14.4.3. SWOT ANALYSIS
14.4.4. KEY STRATEGY
14.5. APTARGROUP, INC.
14.5.1. PRODUCTS OFFERED
14.5.2. SWOT ANALYSIS
14.6. PROCTOR & GAMBLE COMPANY
14.6.1. COMPANY OVERVIEW
14.6.2. PRODUCTS OFFERED
14.6.3. SWOT ANALYSIS
14.6.4. KEY STRATEGY
14.7. RECKITT BENCKISER GROUP PLC
14.7.1. COMPANY OVERVIEW
14.7.2. PRODUCTS
14.7.3. SWOT ANALYSIS
14.7.4. KEY STRATEGY
14.8. SANOFI
14.8.1. PRODUCTS OFFERED
14.8.2. SWOT ANALYSIS
14.9. PERRIGO COMPANY PLC
14.9.1. COMPANY OVERVIEW
14.9.2. SWOT ANALYSIS
14.9.3. KEY STRATEGY
14.10. DR.
14.10.1. COMPANY OVERVIEW
14.10.2. PRODUCTS OFFERED
14.10.3. SWOT ANALYSIS
14.10.4. KEY STRATEGY

15. DATA CITATIONS

16. US DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD BILLION)

17. CANADA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035

18. CANADA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

19. EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035

20. EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD

21. UK DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

22. ITALY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035

23. SPAIN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD

24. REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035

25. REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035

26. CHINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD

27. INDIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035

28. SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL,

29. INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

30. MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035

31. MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

32. AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035

33. AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

34. SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035

35. SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

36. BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035

37. ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035

38. SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035

39. SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL,

40. GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035

41. REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT

42. APTARGROUP, INC. COMPANY: PRODUCTS OFFERED

43. GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE, 2024 (% SHARE)

44. (% SHARE)

45. (% SHARE)

46. SANOFI: SWOT ANALYSIS

47. DR. REDDY’S LABORATORIES: SWOT ANALYSIS